Aeju Lee, Ph.D.
International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Japan
Ph.D., Korea University, School of Medicine (2013)
|2014- 2016||Postdoctral fellow (IIT, Italy)|
|2013- 2014||Postdoctral fellow (KIST, Korea)|
|2009- 2013||MS & Ph.D course trainee (KIST, Korea)|
|2008- 2009||Research Assistant (KIST, Korea)|
Selected peer-reviewed publications
- Lee A et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic MMP 3-specific polymeric probe. Arthritis Rheum 2011
- Lee A et al. Measurement of MMP Activity in Synovial Fluid in Cases of Osteoarthritis and Acute Inflammatory Conditions of the Knee Joints Using a Fluorogenic Peptide Probe-Immobilized Diagnostic Kit. Theranostics 2012
- Lee A et al. A novel near-infrared fluorescence chemosensor for copper ion detection using click ligation and energy transfer. Chem Commun 2013
- Lee A et al. TNF-α Gene Silencing Using Polymerized siRNA/Thiolated Glycol Chitosan Nanoparticles for Rheumatoid Arthritis. Mol Ther 2014
- Lee A et al. Spherical Polymeric Nanoconstructs for Combined Chemotherapeutic and anti-Inflammatory Therapies. Nanomedicine : NBM 2016
- Lee A et al. Dexamethasone-loaded nanoconstructs for treating and monitoring inflammation in murine colitis models”, Theranostics 2017
Research in the Lee lab develop novel molecular imaging sensor and multi-drug delivery carrier for Theragnostics (Therapy + Diagnosis).
1. Enzyme specific activated imaging sensor based real-time in vivo imaging
Proteases are among the most studied enzyme families due to their involvement in the regulation of diverse disease processes and their potential value as biomarkers and therapeutic targets. We reported various protease target Near-infrared fluorescence (NIRF) imaging sensors and detecting pathologic processes at the cellular and molecular levels in vivo, such as cancer, arthritis, brain disorder and inflammation.
2. Combination drug delivery using biocompatible polymer nanoconstructs
Nanoconstructs can simultaneously deliver multiple agents to cancerous lesions enabling de facto combination therapies. We reported that multi-drug loaded nanoconstructs delivery to malignant mass show synergistic effect.